Immune modulation with interleukin-21

Annals of the New York Academy of Sciences

Volumn 1182, Issue , 2009, Pages 39-46

  Bhave, Neela S ^a   Carson III, William E ^a  

^a OHIO STATE UNIVERSITY   (United States)

Author keywords

Innate immunity; Interleukin 21; NK cells; Tumor immunology

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; ALPHA INTERFERON; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; GRANZYME B; IMMUNOGLOBULIN G; INTERLEUKIN 12; INTERLEUKIN 21; INTERLEUKIN 21 RECEPTOR; INTERLEUKIN 21 RECEPTOR ALPHA; INTERLEUKIN 23; INTERLEUKIN 4 ANTIBODY; JANUS KINASE 1; JANUS KINASE 3; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MESSENGER RNA; PERFORIN; PROTEIN BCL 2; PROTEIN BCL X; RANTES; STAT1 PROTEIN; STAT3 PROTEIN; STAT5 PROTEIN; SUPPRESSOR OF CYTOKINE SIGNALING 1; SUPPRESSOR OF CYTOKINE SIGNALING 3; T LYMPHOCYTE RECEPTOR; TRASTUZUMAB; TUMOR NECROSIS FACTOR ALPHA;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; B LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL PROLIFERATION; CLINICAL TRIAL; CONFERENCE PAPER; CYTOKINE RELEASE; CYTOTOXICITY; DENDRITIC CELL; DIZZINESS; DOWN REGULATION; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG EFFICACY; DRUG FEVER; DRUG SAFETY; DRUG TOLERABILITY; GENE EXPRESSION; HUMAN; IMMUNE RESPONSE; IMMUNOMODULATION; INTERFERON PRODUCTION; KIDNEY CARCINOMA; LUNG CANCER; LUNG METASTASIS; MAXIMUM TOLERATED DOSE; MELANOMA; NATURAL KILLER CELL; NEUTROPENIA; NONHUMAN; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REGULATORY MECHANISM; REGULATORY T LYMPHOCYTE; RIGOR; SIDE EFFECT; SIGNAL TRANSDUCTION; T LYMPHOCYTE; TH17 CELL; TREATMENT RESPONSE; TUMOR GROWTH; TUMOR VOLUME; UPREGULATION;

EID: 73849140105     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2009.05071.x     Document Type: Conference Paper

References (52)

1. Parrish-Novak, J., S.R. Dillon, A. Nelson, et al. 2000. Interleukin 21 and its receptor are involved inNKcell expansion and regulation of lymphocyte function. Nature 408: 57-63.
2. Parrish-Novak, J., D.C. Foster, R.D. Holly & C.H. Clegg. 2002. Interleukin-21 and the IL-21 receptor: novel effectors of NK and T cell responses. J. Leukoc. Biol. 72: 856-863.
3. di Carlo, E., D. de Totero, T. Piazza, et al. 2007. Role of IL-21 in immune-regulation and tumor immunotherapy. Cancer Immunol. Immunother. 56: 1323-1334.
4. Davis, I.D., K. Skak, M.J. Smyth, et al. 2007. Interleukin-21 signaling: functions in cancer and autoimmunity. Clin. Cancer Res. 13: 6926-6932.
5. Spolski, R. & W.J. Leonard. 2008. Interleukin-21: basic biology and implications for cancer and autoimmunity. Annu. Rev. Immunol. 26: 57-79.
6. Brady, J., Y. Hayakawa, M.J. Smyth & S.L. Nutt. 2004. IL-21 induces the functional maturation of murine NK cells. J. Immunol. 172: 2048-2058.
7. Burgess, S.J., A.I. Marusina, I. Pathmanathan, et al. 2006. IL-21 down-regulates NKG2D/DAP10 expression on humanNKand CD8+ Tcells. J. Immunol. 176: 1490-1497.
8. Strengell, M., S. Matikainen, J. Siren, et al. 2003. IL-21 in synergy with IL-15 or IL-18 enhances IFNgamma production in human NK and T cells. J. Immunol. 170: 5464-5469.
9. Wang, G., M. Tschoi, R. Spolski, et al. 2003. in vivo antitumor activity of interleukin 21 mediated by natural killer cells. Cancer Res. 63: 9016-9022.
10. Ma, H.L., M.J. Whitters, R.F. Konz, et al. 2003. IL- 21 activates both innate and adaptive immunity to generate potent antitumor responses that require perforin but are independent of IFN-gamma. J. Immunol. 171: 608-615.
11. Di Carlo, E., A.Comes, A.M.Orengo, et al. 2004. IL- 21 induces tumor rejection by specific CTL and IFNgamma- dependent CXC chemokines in syngeneic mice. J. Immunol. 172: 1540-1547.
12. Smyth, M.J., M.E. Wallace, S.L. Nutt, et al. 2005. Sequential activation of NKT cells and NK cells provides effective innate immunotherapy of cancer. J. Exp. Med. 201: 1973-1985.
13. Takaki, R., Y. Hayakawa, A. Nelson, et al. 2005. IL-21 enhances tumor rejection through a NKG2Ddependent mechanism. J. Immunol. 175: 2167-2173.
14. Comes, A., O. Rosso, A.M. Orengo, et al. 2006. CD25+ regulatory T cell depletion augments immunotherapy of micrometastases by an IL-21- secreting cellular vaccine. J. Immunol. 176: 1750-1758.
15. Thompson, J.A., B.D. Curti, B.G. Redman, et al. 2008. Phase I study of recombinant interleukin-21 in patients with metastatic melanoma and renal cell carcinoma. J. Clin. Oncol. 26: 2034-2039.
16. Asao, H., C. Okuyama, S. Kumaki, et al. 2001. Cutting edge: the common gamma-chain is an indispensable subunit of the IL-21 receptor complex. J. Immunol. 167: 1-5.
17. Gagnon, J., S. Ramanathan, C. Leblanc & S. Ilangumaran. 2007. Regulation of IL-21 signaling by suppressor of cytokine signaling-1 (SOCS1) in CD8(+) T lymphocytes. Cell Signal. 19: 806-816.
18. Strengell, M., A. Lehtonen, S. Matikainen & I. Julkunen. 2006. IL-21 enhances SOCS gene expression and inhibits LPS-induced cytokine production in human monocyte-derived dendritic cells. J. Leukoc. Biol. 79: 1279-1285.
19. Zeng,R., R. Spolski, E. Casas, et al. 2007.Themolecular basis of IL-21-mediated proliferation. Blood 109: 4135-4142.
20. Konforte, D., N. Simard & C.J. Paige. 2009. IL-21: An Executor of B Cell Fate. J. Immunol. 182: 1781-1787.
21. Mehta, D.S., A.L.Wurster,M.J.Whitters, et al. 2003. IL-21 induces the apoptosis of resting and activated primary B cells. J. Immunol. 170: 4111-4118.
22. Jin, H.,R. Carrio, A.Yu&T.R.Malek. 2004. Distinct activation signals determine whether IL-21 induces B cell costimulation, growth arrest, or Bim-dependent apoptosis. J. Immunol. 173: 657-665.
23. Mehta, D.S., A.L. Wurster & M.J. Grusby. 2004. Biology of IL-21 and the IL-21 receptor. Immunol. Rev. 202: 84-95.
24. Wurster, A.L., V.L. Rodgers, A.R. Satoskar, et al. 2002. Interleukin 21 is a T helper (Th) cell 2 cytokine that specifically inhibits the differentiation of naive Th cells into interferon gamma-producing Th1 cells. J. Exp. Med. 196: 969-977.
25. Korn, T., E. Bettelli, W. Gao, et al. 2007. IL-21 initiates an alternative pathway to induce proinflammatory T(H)17 cells. Nature 448: 484-487.
26. Nurieva, R., X.O. Yang, G. Martinez, et al. 2007. Essential autocrine regulation by IL-21 in the generation of inflammatory T cells. Nature 448: 480-483.
27. Coquet, J.M., K. Kyparissoudis, D.G. Pellicci, et al. 2007. IL-21 is produced by NKT cells and modulates NKT cell activation and cytokine production. J. Immunol. 178: 2827-2834.
28. Kasaian, M.T.,M.J.Whitters, L.L. Carter, et al. 2002. IL-21 limitsNKcell responses and promotes antigenspecific T cell activation: a mediator of the transition from innate to adaptive immunity. Immunity 16: 559-569.
29. Suto, A., A.L. Wurster, S.L. Reiner & M.J. Grusby. 2006. IL-21 inhibits IFN-gamma production in developing Th1 cells through the repression of Eomesodermin expression. J. Immunol. 177: 3721-3727.
30. Eriksen, K.W., H. Søndergaard, A. Woetmann, et al. 2009. The combination of IL-21 and IFN-[alpha] boosts STAT3 activation, cytotoxicity and experimental tumor therapy. Mol. Immunol. 46: 812-820.
31. Thedrez, A., C. Harly, A. Morice, et al. 2009. IL-21-mediated potentiation of antitumor cytolytic and proinflammatory responses of human V{gamma}9V{delta}2 T cells for adoptive immunotherapy. J. Immunol. 182: 3423-3431.
32. Spolski, R. &W.J. Leonard. 2008. The Yin and Yang of interleukin-21 in allergy, autoimmunity and cancer. Curr. Opin. Immunol. 20: 295-301.
33. Peluso, I., M.C. Fantini, D. Fina, et al. 2007. IL-21 counteracts the regulatory T cell-mediated suppression of humanCD4+ Tlymphocytes. J. Immunol. 178: 732-739.
34. Li, Y. & C. Yee. 2008. IL-21mediated Foxp3 suppression leads to enhanced generation of antigen-specific CD8+ cytotoxic T lymphocytes. Blood 111: 229-235.
35. Medzhitov, R. & C.A. Janeway Jr. 1997. Innate immunity: impact on the adaptive immune response. Curr. Opin. Immunol. 9: 4-9.
36. Mende, I. & E.G. Engleman. 2005. Breaking tolerance to tumors with dendritic cell-based immunotherapy. Ann. N. Y. Acad. Sci. 1058: 96-104.
37. Brandt, K., S. Bulfone-Paus, A. Jenckel, et al. 2003. Interleukin-21 inhibits dendritic cell-mediated T cell activation and induction of contact hypersensitivity in vivo. J. Invest. Dermatol. 121: 1379-1382.
38. Brandt, K., S. Bulfone-Paus, D.C. Foster & R. Ruckert. 2003. Interleukin-21 inhibits dendritic cell activation and maturation. Blood 102: 4090-4098.
39. Brandt, K., P.B. Singh, S. Bulfone-Paus&R.Ruckert. 2007. Interleukin-21: a new modulator of immunity, infection, and cancer. Cytokine Growth Factor Rev. 18: 223-232.
40. Roda, J.M., R. Parihar, A. Lehman, et al. 2006. Interleukin-21 enhances NK cell activation in response to antibody-coated targets. J. Immunol. 177: 120-129.
41. Strbo,N., L. de Armas,H. Liu, et al. 2008. IL-21 augments natural killer effector functions in chronically HIV-infected individuals. Aids 22: 1551-1560.
42. Vosshenrich, C.A. & J.P. Di Santo. 2001. Cytokines: IL-21 joins the gamma(c)-dependent network? Curr. Biol. 11: R175-177.
43. Vosshenrich, C.A., T. Ranson, S.I. Samson, et al. 2005. Roles for common cytokine receptor gammachain- dependent cytokines in the generation, differentiation, and maturation of NK cell precursors and peripheral NK cells in vivo. J. Immunol. 174: 1213-1221.
44. Skak, K., K.S. Frederiksen & D. Lundsgaard. 2008. Interleukin-21 activates human natural killer cells and modulates their surface receptor expression. Immunology 123: 575-583.
45. Sivori, S., C. Cantoni, S. Parolini, et al. 2003. IL- 21 induces both rapid maturation of human CD34+ cell precursors towards NK cells and acquisition of surface killer Ig-like receptors. Eur J. Immunol. 33: 3439-3447.
46. Parihar, R., J. Dierksheide, Y. Hu & W.E. Carson. 2002. IL-12 enhances the natural killer cell cytokine response to Ab-coated tumor cells. J. Clin. Invest. 110: 983-992.
47. Parihar, R., P. Nadella, A. Lewis, et al. 2004. A Phase I Study of Interleukin-12 with trastuzumab in patients with HER2 overexpressing malignancies: Correlation between response and sustained interferongamma production. Clin. Cancer Res. 10: 5027-5037.
48. Roda, J.M., T. Joshi, J.P. Butchar, et al. 2007. The activation of natural killer cell effector functions by cetuximab-coated, epidermal growth factor receptor positive tumor cells is enhanced by cytokines. Clin. Cancer Res. 13: 6419-6428.
49. Davis, I.D., B.K. Skrumsager, J. Cebon, et al. 2007. An open-label, two-arm, phase I trial of recombinant human interleukin-21 in patients with metastatic melanoma. Clin. Cancer Res. 13: 3630-3636.
50. Davis, I.D., B. Brady, R.F. Kefford, et al. 2009. Clinical and biological efficacy of recombinant human interleukin-21 in patients with stage IV malignant melanoma without prior treatment: A phase IIa trial. Clin. Cancer Res. 15: 2123-2129.
51. Curti, B.D. 2006. Immunomodulatory and antitumor effects of interleukin-21 in patients with renal cell carcinoma. Expert Rev. Anticancer Ther. 6: 905-909.
52. Skak, K., M. Kragh, D. Hausman, et al. 2008. Interleukin 21: combination strategies for cancer therapy. Nat. Rev. Drug Discov. 7: 231-240.